MEG3 targets miR-184 and Wnt/β-catenin and modulates properties of osteosarcoma

Liang Li¹, SiBiao Pei², Na Sun³

¹Department of Orthopaedics, Nanchong central hospital, Sichuan province, 637000, PR China, ²Department of pharmacy, Nanchong central hospital, Sichuan province, 637000, PR China, ³Department of endocrinology department, Nanchong central hospital, Sichuan province, 637000, PR China

Table of contents

1. Abstract
2. Introduction
3. Materials and methods
   3.1. Cell lines, clinical samples and animals
   3.2. Cell transfection and MEG3 luciferase reporter assay
   3.3. Osteosarcoma model and groups
   3.4. RT-PCR and quantitative real-time PCR (qPCR)
   3.5. CCK-8 assay
   3.6. Analysis of apoptosis
   3.7. Transwell mobility assay
   3.8. Western bloting
   3.9. TOP/FOP-FLASH luciferase reporter assay
   3.10. Immunohistochemical staining
   3.11. Statistical analysis
4. Results
   4.1. Expression of MEG3 and miR-184 in OS
   4.2. MEG3 regulates the OS tumor cell properties by targeting miR-184
   4.3. MEG3 represses the Wnt/β-catenin pathway via targeting miR-184
   4.4. MEG3 inhibits the OS by targeting miR-184 in vivo
5. Discussion
6. References

1. ABSTRACT

Recent studies indicate that MEG3, a long non-coding RNA (lncRNA) and microRNA-184 (miR-184) are abnormally expressed in osteosarcoma (OS). To this end, we show here that MEG3 negatively regulates the expression of miR-184 and down-stream effectors of WNT/β-catenin pathway including β-catenin, T-cell factor 4 (TCF4) and c-MYC. MEG3 overexpression by adenoviral vectors down-regulate proliferation, migration and apoptosis of OS in vitro and restrict the tumor growth in vivo. We also show that the effects of MEG3 can be effectively reversed by miR-184 mimic. Together these studies show that both MEG3 and miR-184 cooperatively regulate the proliferation, migration and apoptosis of OS.

2. INTRODUCTION

Osteosarcoma (OS) is one of the most common solid bone cancers in children and adolescents that carries a high morbidity and mortality. This tumor usually affects proximal
MEG3/miR-184 suppresses OS

humerus or tibia and the metaphysis of distal femur (1). Typical symptoms of OS include limitation of joint movement, trabecular fracture, local swelling and pain (2). Other than surgery, the traditional treatments including post-operative radiotherapy and chemotherapy may lead to life-threatening side effects such as nephrotoxicity, infertility and cardiotoxicity. Therefore, There is a need for better understanding of the pathogenesis of OS with the hope to develop better treatment strategies with fewer side effects.

Maternally Expressed Gene 3 (MEG3), is a lncRNA, with key role in various cancers (3,4). Some earlier work suggested that MEG3 is poorly expressed in OS and might be a potential target for the treatment of this cancer (5). Other studies have shown that the expression of diverse miRNAs including miRNA-184 is deregulated in OS and other cancers and these changes might be used for assessment of prognosis (6-9). MEG3 interacted with miR-184 and subsequently alleviated the proliferation and invasion of leukemia cells by down-regulating related proteins (10). Wnt/β-catenin pathway plays essential roles in the tumorigenesis and EMT and is thought to be involved in the occurrence and tumor progression and metastasis of OS (11,12). It has also been shown that in retinoblastoma, reduced MEG3, resulted led to the tumor progression by regulating the activity of Wnt/β-catenin pathway (13-14). Based on such a background, we hypothesized and tested whether miR-184/MEG3/β-catenin axis may be involved in the pathogenesis of OS.

3. MATERIALS AND METHODS

3.1. Cell lines, clinical samples and animals

MG63, U2OS and normal osteoblast hFOB1.19 cell lines were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA). All cells were cultured in RPMI-1640 (Gibco, Rockville, MD, USA) supplemented with 10% FBS at 37°C with 5% CO2. Samples of OS tumors the adjacent non-involved tissues of 55 patients who underwent surgery were frozen and stored at -80°C from following an approved protocol of the Ethics Committee of Nanchong central hospital. Patients did not receive radiotherapy or chemotherapy before surgery. Nude mice (6-8 weeks old) were obtained from Animal Experimental Center of Nanchong central hospital following a protocol approved by the Committee on the Ethics of Nanchong central hospital. MG63 cells with good growth were made as a single cell suspension of 5 × 10^6 cells. U2OS cells with good growth were made as a single cell suspension of 5 × 10^5. 0.4 mL 5×10^6 MG63 cells were subcutaneously injected into the right armpit and 2×10^6 MG63 cells were introduced to the skin to form xenograft tumors.

3.2. Cell transfection and MEG3 luciferase reporter assay

TargetScan and miRanda software revealed the existence of a high probability of interaction between miR-184 and MEG3. MEG3 wild type (MEG3 wt), MEG3 mutant (MEG3 mut), negative control mimics (miR-NC), miR-184 mimic, pcDNA-MEG3 and pcDNA vector were obtained from GenePharma Co., Ltd (Shanghai, China). MG63 and U2OS cells were transfected using Lipofectamine 2000 (Invitrogen, Camarillo, CA, USA). The experimental protocol was performed according to the manufacture's instruction. Cells were used 48 h after transduction with pcDNA or after transfection.

3.3. Osteosarcoma model and groups

Nude mice were randomly divided into two groups (n=18). Control group was comprised of nude mice receiving subcutaneous injection of 2×10^5 MG63 cells transfected with empty vector; pcDNA-MEG3, and those receiving subcutaneous injection of 2×10^6 MG63 cells transfected with pcDNA-MEG3. Tumor volume was assessed every five days including the day 30 after injection using the formula: volume=length×width^2×0.5. Percent survival was recorded every three days up to and including the day 27 after injection.

3.4. RT-PCR and quantitative real-time PCR (qPCR)

Total RNA and miRNA were isolated from OS, and its adjacent non-involved tissues and
MEG3/miR-184 suppresses OS

MG63, U2OS and hFOB1.19 cell lines according to the manufacturer’s instructions. The PCR primers for MEG3, miR-184 and GAPDH were purchased from Ribobio (Guangzhou, China) (the primer sequences in Table 1). 10 ng total RNA of each sample was used to analysis miRNA expression. Total RNA transcribed into cDNA using TaqMan® MicroRNA Reverse Transcription kit (Huiying, Shanghai, China). TaqMan® 2× Universal PCR Master Mix no UNG (Applied Biosystems) was used to perform qRT-PCR. PCR parameters were as follows: 55°C for 1 min, followed by 35 cycles (denature: 92°C for 30 sec then 58°C for 45 sec; elongation at 72°C for 35 sec). CT values of all samples and standard reference were calculated by fluorescent quantitative PCR cycler (PE, US). All experiments were carried out in triplicates and results of qPCR were assessed using ABI 7500 Fast Realtime PCR system (Applied Biosystems, Life Technologies, USA). The relative expression of miR-184 and MEG3 was determined using the 2^−ΔΔCt method.

3.5. CCK-8 assay

The viability of MG63 and U2OS cell lines was evaluated using CCK-8 assay that allows sensitive colorimetric determination of cytotoxicity, cell viability and cell proliferation as described previously (15). The kit was obtained from Shanghai Xiya Biotechnology Co., Ltd (Shanghai, China). and analysis was carried out 48 h post-transfection. The OD values were assessed using a spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA).

3.6. Analysis of apoptosis

Using fluorescein isothiocyanate (FITC) - labeled Annexin V (KeyGEN Biotech, Nanjing, China), apoptosis in MG63 and U2OS cells was assessed by flow cytometry 48 h after transfection as described previously (16). Apoptotic cells were also identified in 3 μm thick sections of OS tumors from mice by TUNEL assay by a kit (Name of company, City and state) and as described previously (17). Images (×400) were captured using a light microscope (Olympus, Tokyo, Japan).

3.7. Transwell mobility assay

The transfected cells were lysed with trypsin and adjusted at 1 × 10^5 cells/mL density. Then cells added into the upper chambers coated with 150 μg of Matrigel (BD, New Jersey, USA) and the lower chamber was filled with RPMI-1640 medium containing 10% FBS. Upon 24h incubation, non-invasive cells were washed away and the invasive cells were fixed in methanol and stained with crystal violet (Sigma, MO, USA) for 15 min. Finally, the invading cells were photographed under an optical microscope (Olympus, Tokyo, Japan).

3.8. Western blotting

The abundance of Ki67, cleaved caspase-3, vascular endothelial growth factor (VEGF), β-catenin, T-cell factor 4 (TCF4) and c-MYC (Abcam, Cambridge, UK) were assessed by Western blotting referred to previous literature reports (18,19). GAPDH was used as the house-keeping control. Immunoreactive bands were visualized by Chemiluminescent ECL Reagent Kit (Milipore, Bedford, MA, USA). Quantitation of signal intensities was performed by densitometry on a Xerox scanner using NIH ImageJ software.

3.9. TOP/FOP-FLASH luciferase reporter assay

TOP/FOP-FLASH is a method for measuring intracellular β-catenin-mediated transcriptional activity (classic wnt signaling pathway). Interactions between Tcf4 and β-catenin are responsible for activation of transcription of many tumor-related proteins (20). β-catenin and TCF4 can show co-localization relationship.TOP/FOP-FLASH

Table 1. Primer sequences

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer 5'-3'</th>
<th>Reverse primer 5'-3'</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEG3</td>
<td>CTGCCATCTACACCTCACG</td>
<td>CTCTCCGCGTCTGCGCTAGGGGCT</td>
</tr>
<tr>
<td>miR-184</td>
<td>TACGACTATGTGACCTGCTG</td>
<td>TGGTTCAGCTCTCCTTTCCA</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GGCTTCCGTGGTCTCAC</td>
<td>TGTCATCATATCTGGCAGGT</td>
</tr>
</tbody>
</table>
MEG3/miR-184 suppresses OS

luciferase reporter assay was performed as reported previously (21). Briefly, transfected MG63 cells in each group were incubated with mixture containing serum-free DMEM (20 µL), β-catenin expression vector (1.5 µg), TCF4 expression vector (0.15 µg) and Renilla luciferase vector phRG-TK (0.8 ng). 24 h later, luciferase activity was measured by a luminometer (Zhongmei, Xi’an, China).

3.10. Immunohistochemical staining

Tumor were fixed in 10% formalin, embedded in paraffin, sectioned at 3 µm and immunostained using antibodies to Ki67 (Abcam, Cambridge, UK), anti-caspase-3 (Abcam, Cambridge, UK), anti-VEGF (Abcam, Cambridge, UK), anti-β-catenin (Abcam, Cambridge, UK). using antibodies. Sections were photographed (×400) using a optical microscope.

3.11. Statistical analysis

All statistical analysis were conducted using the SPSS statistical software program (version 17.0; SPSS, Inc., Chicago, IL). The data presented in this study were expressed as means± SD. Statistical differences were analyzed by one-way ANOVA. P values < 0.05 were considered statistically significant.

4. RESULTS

4.1. Expression of MEG3 and miR-184 in OS

The expression of MEG3 and miR-184 was assed by RT-PCR followed by qPCR. The expression of MEG3 was reduced while the expression of miR-184 was increased in OS as compared to adjacent non-involved tissues showing an inverse relationship between the expression of MEG3 and miR-184 (Figure 1A-B). Carrying out the same analysis in normal osteoblast cell line, hFOB1.19, and human OS cell lines (MG63 and U2OS) showed the same trend and of existence of an inverse relation between the expression of MEG3 and miR-184 (Figure 1C).

To decipher of the cause of such an inverse correlation, using the online software Diana Tools (http://diana.imis.athena-innovation.gr), we analyzed the MEG3 elements that were complementary to and were potential binding site for miR-184. This analysis revealed of existence of many elements that were complementary to miR-184 in MEG3 (Figure 2A). To formally test such an interaction, we transduced MG63 and U2OS cells with empty control, pcDNA vector and pcDNA-MEG3(20 μg/mL). Following transduction, while the expression of MEG3 was increased significantly in MG63 and U2OS cells, the expression of miR-184 was significantly reduced (Figure 2B). In addition, we transected MEG63 and U2OS cells with empty control, NC mimics and miR-184 mimic. Upon transfection, the expression of miR-184 was increased significantly in MG63 and U2OS.
MEG3/miR-184 suppresses OS

Figure 2. MEG3 directly interacts with miR-184. A. The sequence of miR-184, MEG3 wt and MEG3 mut. B. The expression levels of MEG3 and miR-184 were evaluated by RT-PCR followed by qPCR in MG63 and U2OS cells transfected with or without pcDNA-MEG3. C. The level of miR-184 was assessed using RT-PCR followed by qPCR in MG63 and U2OS cells transfected with or without miR-184 mimic. D. Relative luciferase activities of wild type (WT) and mutated (Mut) MEG3 reporter plasmid in MG63 and U2OS cells cotransfected with miR-184. Description: The experiments were repeated at least 3 times. Error bars represent ± SD. (\(^* P < 0.01\), \(** P < 0.001\) versus control group; \(## P < 0.01\) versus miR-184 mimic group). Notice: the expression of MEG3 and miR-184 in the control was considered as 1; miR NC: negative control miR mimics; control: cells did not be transfected.

We then examined the effect of MEG3 and miR-184 mimic on in vitro mobility and invasiveness of OS. Figure 3D shows that while cells that transduction with pcDNA-MEG3 decreased the number of cells that migrated from the upper to the lower chamber, this mobility was enhanced by transfection of cells with miR-184 mimic (Figure 3D). Moreover, the number of invasive cells was reduced in pcDNA-MEG3 group as compared to the control or miR-184 mimic group and this enhanced mobility was recovered after transfection with miR-184 (Figure 3D).

4.3. MEG3 represses the Wnt/β-catenin pathway via targeting miR-184

Given that Wnt/β-catenin is involved in tumor progression, we considered the possibility that MEG3/miR-184 might down-regulate Wnt/β-catenin in OS. To do this, we carried out Western blotting of Wnt/β-catenin including its members and effectors such as GSK3 β Axin1, APC, β -catenin, TCF4, c-Myc, using GAPDH as a housekeeping control. Transduction with pcDNA-MEG3 decreased β-catenin, TCF4 and c-MYC while transfection with miR-184 enhanced such effects (Figure 4A).

To further validate these results, cells were transfected with Renilla luciferase vector phRG-TK;
MEG3/miR-184 suppresses OS

(0.8 ng), β-catenin expression vector (1.5 µg), or TCF4 expression vector (0.15 µg). Compared with the control group, the expression of β-catenin was decreased in cells transfected with pcDNA-MEG3, showing lower reporter gene activity, while the cells transfected with miR-184 mimics significantly enhanced β-catenin expression, showing higher TOP-FLASH transactivation (Figure 4B).

4.4. MEG3 inhibits the OS by targeting miR-184 in vivo

Together, these findings show that MEG3 regulates different attributes of OS. To further validate these findings, in vivo, MG63 tumor cells were transduced without and with pcDNA-MEG3 and then the tumor volume was assessed every five days up to 30 days. In these while the expression of MEG3 was significantly increased the expression of miR-184 was highly suppressed (Figure 5C). Moreover, tumor volume was significantly decreased and the survival of mice increased in mice with tumors that were transduced with pcDNA-MEG3 (Figure 5A-B).

Tumors that were transduced with pcDNA-MEG3 showed a decreased β-catenin, marked reduced Ki67 and a higher level of apoptosis as evidenced by TUNEL and caspase 3 immunostaining as compared with the control group (Figure 5D).

5. DISCUSSION

Available evidence suggests that lncRNAs are implicated in tumor development and that their expression is subjected to silencing X chromosome, transcriptional activation, genomic imprinting and chromatin modification (22). Here, we carried out TargetScan and miRanda and, as orginally suggested by Li J et al., the results predicted the probability of an interaction between miR-184 and MEG3 (10). Moreover, we find that the expression of miRNA-184 is significantly increased in OS, and OS cell lines (MG63 and U2OS) while in the same tumors MEG3 was repressed. We further validated of the
MEG3/miR-184 suppresses OS

MEG3/miR-184 suppresses OS

Figure 4. MEG3 suppresses the Wnt/β-catenin pathway via targeting miR-184. MG63 cells were randomly divided into 4 groups: Control group, pcDNA-MEG3 group, miR-184 mimic group, pcDNA-MEG3 + miR-184 mimic group. A. Western blotting of GSK3β, Axin1, APC, β-catenin, TCF4, and c-MYC. B. lane 1: MG63 cells were transfected with the TOP- or FOP-FLASH firefly luciferase reporter plasmids including empty expression vectors, or with β-catenin and TCF-4 expression vectors. Data are presented as fold induction relative to the co-transfection of the reporter plasmid (either TOP- or FOP-FLASH) with the empty expression vectors. The experiments were repeated at least 3 times. Error bars represent ± SD. (*P < 0.05, **P < 0.01, ***P < 0.001 versus control group; # P < 0.05, ## P < 0.01 versus miR-184 mimic group).

inverse relation between miR-184 and MEG3 using the online software Diana Tools (http://diana.imis.athena-innovation.gr), and find that there are elements in MEG3 that are complementary to and are potential binding site for miR-184. Following transduction of cells with MEG3, while the expression of MEG3 was increased significantly in MG63 and U2OS cells, the expression of miR-184 was significantly reduced. We also showed that while the luciferase activity of miR-184 is reduced in MG63 and U2OS cells that overexpressed MEG3. Thus, the results
MEG3/miR-184 suppresses OS

and MEG3. Moreover, we showed that the interplay between MEG3 and miR-184 jointly regulate tumor cell attributes including proliferation, apoptosis and mobility of cancer cells lines in vitro. MEG3 overexpression led to a decreased Ki67 positive cells, while increasing caspase-3.

As previously suggested, our findings are consistent with the notion that MEG3 IncRNA appears to be a tumor suppressor in OS (23). Sahin et al. showed that miR-664a and MEG3 interact and that inhibition of miR-664a interferes with the migration of osteosarcoma cells via modulation of MEG3 (5). Sun et al. demonstrated that growth and metastasis of OS cells were promoted by IncRNA EWSAT1 by repressing the expression of MEG3 (24). Moreover, the expression of miRNAs, which is regulated at a post-transcriptional level, has been shown to be deregulated in diverse forms of cancer (25). Among these, miR-184 seems to control proliferation, and apoptosis of diverse forms of cancers including ovarian cancer (7). In line with such role, the upregulation of miR-184 enhanced the malignant biological behavior of human glioma cell line A172 by targeting FIH-1 (26).

These findings are consistent with other reports including regulation of growth and migration and apoptosis in diverse tumors and cell types. For example, the proliferation of human hepatoma cells was strongly suppressed and apoptosis was induced by ectopic expression of MEG3 in vivo (27). The migration and proliferation of artery smooth muscle cells were triggered by down-regulation of MEG3 through p53 signaling pathway (28). As a prognostic factor for colorectal cancer, MEG3 promoted chemosensitivity by elevating oxapliplatin-induced cell apoptosis (29). It has also been reported that miR-184 plays an important role in proliferation of hepatocellular carcinoma by loss of INPPL1 and serves as an anti-apoptotic factor by suppressing the expression of caspase-3 and caspase-7 (30). In a nude mouse breast cancer xenograft model, overexpression of MEG3 suppressed angiogenesis and tumorigenesis (31). Similarly, in our study, the growth rate of tumor was

Figure 5. MEG3 inhibits OS via targeting miR-184 in vivo. Nude mice were randomly divided into groups; those received MG63 tumor cells without or after being transduced with pcDNA-MEG3. Tumor volume (A), percent survival (B) were assessed on different days after introduction to the tumor cells. C. Paraffin sections of tumors were immunostained for Ki67, β-catenin, caspase 3 and TUNEL. The experiments were repeated at least 3 times. Error bars represent ± SD. ( * P < 0.05, ** P < 0.01, *** P < 0.001 versus control group).
MEG3/miR-184 suppresses OS significantly repressed while survival rate and apoptosis remarkably elevated by MEG3 overexpression in vivo.

Under normal conditions, osteoblast differentiation and bone formation appear to be under the regulation of Wnt/β-catenin pathway (32). Wnt/β-catenin pathway also seems to play a significant role in diverse cancers in regulating their proliferation, motility and differentiation. For example, Gao Y et al. showed that MEG3 negatively regulated the activity of Wnt/β-catenin pathway in the development of retinoblastoma (13). Cisplatin resistance of lung cancer cells was increased by down-regulated MEG3 via the activation of the Wnt/β-catenin (33). In keeping with these studies, we showed that in OS cell lines, MEG3 suppressed the expression of β-catenin, TCF4 and c-MYC that was inducible by miR-184 in MG63 cells in vitro and also suppressed the β-catenin only in tumor cells that were transduced with pcDNA-MEG3 in vivo. Together, the results of this study demonstrated that MEG3 is involved in regulation of OS tumor cell behavior by regulation of miR-184 and impacting the Wnt/β-catenin (Figure 6). This result can provide a basis for target research in the treatment of osteosarcoma.

6. REFERENCES


MEG3/miR-184 suppresses OS

184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation. Die Pharmazie, 70(10), 668-73 (2015).


17. X. Lv, J. Yan, J. Jiang, X. Zhou, Y. Lu, H. Jiang: MicroRNA-27a-3p suppression of peroxisome proliferator-activated receptor-gamma contributes to cognitive impairments resulting from sevoflurane treatment. Journal of


Artery Smooth Muscle Cell Proliferation and Migration via the p53 Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 42(6), 2569-2581 (2017)
DOI: 10.1159/000480218

DOI: 10.3892/or.2017.5828

DOI: 10.1016/j.biopha.2013.09.005

DOI: 10.1177/1010428317701311


DOI: 10.3892/mmr.2015.3897

Abbreviations: IncRNA: long non-coding RNA; MEG3: Maternally Expressed Gene 3; OS: osteosarcoma; miRNA: MicroRNA; VEGF: vascular endothelial growth factor; TCF4: T-cell factor 4; FITC: fluorescein isothiocyanate; PCNA: Protein levels of proliferating cell nuclear antigen; BCL-2: B-cell lymphoma 2; MMP9: matrix metalloproteinase 9; NC mimics: negative control mimics; MEG3 wt, MEG3 wild type; MEG3 mut, MEG3 mutant.

Key Words: MEG3, Osteosarcoma, miR-184, Wnt/β-catenin

Send correspondence to: Liang Li, Nanchong central hospital. 97 Renmin South Road, Shunqing district, Nanchong, Sichuan, PR China, Tel: 86-027-67812888, Fax: 86-027-67812888, E-mail: v2s5w0@sina.com